494 related articles for article (PubMed ID: 24819935)
1. Stimulant and other substance use disorders in schizophrenia: prevalence, correlates and impacts in a population sample.
Sara GE; Burgess PM; Malhi GS; Whiteford HA; Hall WC
Aust N Z J Psychiatry; 2014 Nov; 48(11):1036-47. PubMed ID: 24819935
[TBL] [Abstract][Full Text] [Related]
2. Differences in associations between cannabis and stimulant disorders in first admission psychosis.
Sara G; Burgess P; Malhi GS; Whiteford H; Hall W
Schizophr Res; 2013 Jul; 147(2-3):216-22. PubMed ID: 23684162
[TBL] [Abstract][Full Text] [Related]
3. [Cannabis and schizophrenia: demographic and clinical correlates].
Dervaux A; Laqueille X; Bourdel MC; Leborgne MH; Olié JP; Lôo H; Krebs MO
Encephale; 2003; 29(1):11-7. PubMed ID: 12640322
[TBL] [Abstract][Full Text] [Related]
4. Cannabis and stimulant disorders and readmission 2 years after first-episode psychosis.
Sara GE; Burgess PM; Malhi GS; Whiteford HA; Hall WC
Br J Psychiatry; 2014 Jun; 204(6):448-53. PubMed ID: 24578446
[TBL] [Abstract][Full Text] [Related]
5. Stimulant use disorders: characteristics and comorbidity in an Australian population sample.
Sara G; Burgess P; Harris M; Malhi GS; Whiteford H; Hall W
Aust N Z J Psychiatry; 2012 Dec; 46(12):1173-81. PubMed ID: 22990432
[TBL] [Abstract][Full Text] [Related]
6. The impact of cannabis and stimulant disorders on diagnostic stability in psychosis.
Sara GE; Burgess PM; Malhi GS; Whiteford HA; Hall WC
J Clin Psychiatry; 2014 Apr; 75(4):349-56. PubMed ID: 24813404
[TBL] [Abstract][Full Text] [Related]
7. Exploration of the comorbidity of cannabis use disorders and mental health disorders among inpatients presenting to all hospitals in New South Wales, Australia.
Lai HM; Sitharthan T
Am J Drug Alcohol Abuse; 2012 Nov; 38(6):567-74. PubMed ID: 22746224
[TBL] [Abstract][Full Text] [Related]
8. Alcohol and substance use by patients with psychosis presenting to an emergency department: changing patterns.
Latt N; Jurd S; Tennant C; Lewis J; Macken L; Joseph A; Grochulski A; Long L
Australas Psychiatry; 2011 Aug; 19(4):354-9. PubMed ID: 21851228
[TBL] [Abstract][Full Text] [Related]
9. Comparisons between psychosis samples with different patterns of substance use recruited for clinical and epidemiological studies.
Baker A; Bucci S; Lewin TJ; Richmond R; Carr VJ
Psychiatry Res; 2005 Apr; 134(3):241-50. PubMed ID: 15892983
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder.
Miles H; Johnson S; Amponsah-Afuwape S; Finch E; Leese M; Thornicroft G
Psychiatr Serv; 2003 Apr; 54(4):554-61. PubMed ID: 12663845
[TBL] [Abstract][Full Text] [Related]
11. People living with psychotic illness in 2010: the second Australian national survey of psychosis.
Morgan VA; Waterreus A; Jablensky A; Mackinnon A; McGrath JJ; Carr V; Bush R; Castle D; Cohen M; Harvey C; Galletly C; Stain HJ; Neil AL; McGorry P; Hocking B; Shah S; Saw S
Aust N Z J Psychiatry; 2012 Aug; 46(8):735-52. PubMed ID: 22696547
[TBL] [Abstract][Full Text] [Related]
12. Premorbid cannabis use is associated with more symptoms and poorer functioning in schizophrenia spectrum disorder.
Ringen PA; Nesvåg R; Helle S; Lagerberg TV; Lange EH; Løberg EM; Agartz I; Andreassen OA; Melle I
Psychol Med; 2016 Nov; 46(15):3127-3136. PubMed ID: 27534999
[TBL] [Abstract][Full Text] [Related]
13. Does accumulating exposure to illicit drugs bring forward the age at onset in schizophrenia?
Power BD; Dragovic M; Jablensky A; Stefanis NC
Aust N Z J Psychiatry; 2013 Jan; 47(1):51-8. PubMed ID: 23042939
[TBL] [Abstract][Full Text] [Related]
14. Reasons for increased substance use in psychosis.
Gregg L; Barrowclough C; Haddock G
Clin Psychol Rev; 2007 May; 27(4):494-510. PubMed ID: 17240501
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of substance abuse in schizophrenia: demographic and clinical correlates.
Mueser KT; Yarnold PR; Levinson DF; Singh H; Bellack AS; Kee K; Morrison RL; Yadalam KG
Schizophr Bull; 1990; 16(1):31-56. PubMed ID: 2333480
[TBL] [Abstract][Full Text] [Related]
16. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective.
Hambrecht M; Häfner H
Aust N Z J Psychiatry; 2000 Jun; 34(3):468-75. PubMed ID: 10881971
[TBL] [Abstract][Full Text] [Related]
17. Cannabis and Alcohol Abuse Among First Psychotic Episode Inpatients.
Katz G; Kunyvsky Y; Hornik-Lurie T; Raskin S; Abramowitz MZ
Isr J Psychiatry Relat Sci; 2016; 53(3):10-15. PubMed ID: 28492376
[TBL] [Abstract][Full Text] [Related]
18. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
[TBL] [Abstract][Full Text] [Related]
19. Specific impact of stimulant, alcohol and cannabis use disorders on first-episode psychosis: 2-year functional and symptomatic outcomes.
Ouellet-Plamondon C; Abdel-Baki A; Salvat É; Potvin S
Psychol Med; 2017 Oct; 47(14):2461-2471. PubMed ID: 28424105
[TBL] [Abstract][Full Text] [Related]
20. Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis.
Rubio G; Marín-Lozano J; Ferre F; Martínez-Gras I; Rodriguez-Jimenez R; Sanz J; Jimenez-Arriero MA; Carrasco JL; Lora D; Jurado R; López-Trabada JR; Palomo T
Compr Psychiatry; 2012 Nov; 53(8):1063-70. PubMed ID: 22682680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
